CVC Strategic Opportunities II has agreed to sell its entire stake in Genetic SpA, a pharmaceutical contract development and manufacturing organisation that focuses on the dossier development and supply of products for the Respiratory, Ophthalmic and Oncology therapeutic areas.
During CVC’s partnership with Genetic and the founding Pavese family, the company has developed significantly, expanding internationally from approximately 20 countries in 2020 to 40+ today, broadened its R&D pipeline and committed to the construction of a new production facility to meet growing global demand for its products. These initiatives, as well as others, have resulted in Genetic more than doubling revenues since CVC’s ownership.
CVC’s exit will see NB Renaissance and NB Aurora become shareholders alongside the Pavese family, which will also increase its stake.
Headquartered in Fisciano, Italy, Genetic is a specialised and integrated pharmaceutical CDMO focused on the research, development, manufacturing, licensing, and promotion of pharmaceutical specialties and medical devices. Its primary expertise is in the development of Respiratory and Ophthalmology products, which are delivered via unit-dose Blow-Fill-Seal technology, pressurised Metered Dose Inhalers,nasal sprays and eye drop/collyrium technologies.
Genetic’s products are commercialised by a network of blue chip pharma partners internationally as well as by its own distribution arm (Genetic Farma) in Italy, often under well-recognised local brand names.
CVC was advised by Rothschild & Co., PedersoliGattai, FRM Tax, BCG and PwC.
